<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241123090918&amp;utm_source=Chrome&amp;utm_medium=rss
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241123090918&amp;utm_source=Chrome&amp;utm_medium=rss" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 23 Nov 2024 14:09:19 +0000</lastbuilddate>
<pubDate>Fri, 22 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Exercise training in long COVID: the EXER-COVID trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39575513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 22:ehae721. doi: 10.1093/eurheartj/ehae721. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39575513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39575513</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae721>10.1093/eurheartj/ehae721</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39575513</guid>
<pubDate>Fri, 22 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Robinson Ramírez-Vélez</dc:creator>
<dc:creator>Julio Oteiza</dc:creator>
<dc:creator>Gaizka Legarra-Gorgoñon</dc:creator>
<dc:creator>Sergio Oscoz-Ochandorena</dc:creator>
<dc:creator>Nora García-Alonso</dc:creator>
<dc:creator>Yesenia García-Alonso</dc:creator>
<dc:creator>María Correa-Rodríguez</dc:creator>
<dc:creator>Adrian Soto-Mota</dc:creator>
<dc:creator>Mikel Izquierdo</dc:creator>
<dc:date>2024-11-22</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Exercise training in long COVID: the EXER-COVID trial</dc:title>
<dc:identifier>pmid:39575513</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae721</dc:identifier>
</item>
<item>
<title>Evolutionary genomics of the emergence of brown algae as key components of coastal ecosystems</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39571576/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>Brown seaweeds are keystone species of coastal ecosystems, often forming extensive underwater forests, and are under considerable threat from climate change. In this study, analysis of multiple genomes has provided insights across the entire evolutionary history of this lineage, from initial emergence, through later diversification of the brown algal orders, down to microevolutionary events at the genus level. Emergence of the brown algal lineage was associated with a marked gain of new...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 18:S0092-8674(24)01272-8. doi: 10.1016/j.cell.2024.10.049. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Brown seaweeds are keystone species of coastal ecosystems, often forming extensive underwater forests, and are under considerable threat from climate change. In this study, analysis of multiple genomes has provided insights across the entire evolutionary history of this lineage, from initial emergence, through later diversification of the brown algal orders, down to microevolutionary events at the genus level. Emergence of the brown algal lineage was associated with a marked gain of new orthologous gene families, enhanced protein domain rearrangement, increased horizontal gene transfer events, and the acquisition of novel signaling molecules and key metabolic pathways, the latter notably related to biosynthesis of the alginate-based extracellular matrix, and halogen and phlorotannin biosynthesis. We show that brown algal genome diversification is tightly linked to phenotypic divergence, including changes in life cycle strategy and zoid flagellar structure. The study also showed that integration of large viral genomes has had a significant impact on brown algal genome content throughout the emergence of the lineage.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39571576/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39571576</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.049>10.1016/j.cell.2024.10.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39571576</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>France Denoeud</dc:creator>
<dc:creator>Olivier Godfroy</dc:creator>
<dc:creator>Corinne Cruaud</dc:creator>
<dc:creator>Svenja Heesch</dc:creator>
<dc:creator>Zofia Nehr</dc:creator>
<dc:creator>Nachida Tadrent</dc:creator>
<dc:creator>Arnaud Couloux</dc:creator>
<dc:creator>Loraine Brillet-Guéguen</dc:creator>
<dc:creator>Ludovic Delage</dc:creator>
<dc:creator>Dean Mckeown</dc:creator>
<dc:creator>Taizo Motomura</dc:creator>
<dc:creator>Duncan Sussfeld</dc:creator>
<dc:creator>Xiao Fan</dc:creator>
<dc:creator>Lisa Mazéas</dc:creator>
<dc:creator>Nicolas Terrapon</dc:creator>
<dc:creator>Josué Barrera-Redondo</dc:creator>
<dc:creator>Romy Petroll</dc:creator>
<dc:creator>Lauric Reynes</dc:creator>
<dc:creator>Seok-Wan Choi</dc:creator>
<dc:creator>Jihoon Jo</dc:creator>
<dc:creator>Kavitha Uthanumallian</dc:creator>
<dc:creator>Kenny Bogaert</dc:creator>
<dc:creator>Céline Duc</dc:creator>
<dc:creator>Pélagie Ratchinski</dc:creator>
<dc:creator>Agnieszka Lipinska</dc:creator>
<dc:creator>Benjamin Noel</dc:creator>
<dc:creator>Eleanor A Murphy</dc:creator>
<dc:creator>Martin Lohr</dc:creator>
<dc:creator>Ananya Khatei</dc:creator>
<dc:creator>Pauline Hamon-Giraud</dc:creator>
<dc:creator>Christophe Vieira</dc:creator>
<dc:creator>Komlan Avia</dc:creator>
<dc:creator>Svea Sanja Akerfors</dc:creator>
<dc:creator>Shingo Akita</dc:creator>
<dc:creator>Yacine Badis</dc:creator>
<dc:creator>Tristan Barbeyron</dc:creator>
<dc:creator>Arnaud Belcour</dc:creator>
<dc:creator>Wahiba Berrabah</dc:creator>
<dc:creator>Samuel Blanquart</dc:creator>
<dc:creator>Ahlem Bouguerba-Collin</dc:creator>
<dc:creator>Trevor Bringloe</dc:creator>
<dc:creator>Rose Ann Cattolico</dc:creator>
<dc:creator>Alexandre Cormier</dc:creator>
<dc:creator>Helena Cruz de Carvalho</dc:creator>
<dc:creator>Romain Dallet</dc:creator>
<dc:creator>Olivier De Clerck</dc:creator>
<dc:creator>Ahmed Debit</dc:creator>
<dc:creator>Erwan Denis</dc:creator>
<dc:creator>Christophe Destombe</dc:creator>
<dc:creator>Erica Dinatale</dc:creator>
<dc:creator>Simon Dittami</dc:creator>
<dc:creator>Elodie Drula</dc:creator>
<dc:creator>Sylvain Faugeron</dc:creator>
<dc:creator>Jeanne Got</dc:creator>
<dc:creator>Louis Graf</dc:creator>
<dc:creator>Agnès Groisillier</dc:creator>
<dc:creator>Marie-Laure Guillemin</dc:creator>
<dc:creator>Lars Harms</dc:creator>
<dc:creator>William John Hatchett</dc:creator>
<dc:creator>Bernard Henrissat</dc:creator>
<dc:creator>Galice Hoarau</dc:creator>
<dc:creator>Chloé Jollivet</dc:creator>
<dc:creator>Alexander Jueterbock</dc:creator>
<dc:creator>Ehsan Kayal</dc:creator>
<dc:creator>Andrew H Knoll</dc:creator>
<dc:creator>Kazuhiro Kogame</dc:creator>
<dc:creator>Arthur Le Bars</dc:creator>
<dc:creator>Catherine Leblanc</dc:creator>
<dc:creator>Line Le Gall</dc:creator>
<dc:creator>Ronja Ley</dc:creator>
<dc:creator>Xi Liu</dc:creator>
<dc:creator>Steven T LoDuca</dc:creator>
<dc:creator>Pascal Jean Lopez</dc:creator>
<dc:creator>Philippe Lopez</dc:creator>
<dc:creator>Eric Manirakiza</dc:creator>
<dc:creator>Karine Massau</dc:creator>
<dc:creator>Stéphane Mauger</dc:creator>
<dc:creator>Laetitia Mest</dc:creator>
<dc:creator>Gurvan Michel</dc:creator>
<dc:creator>Catia Monteiro</dc:creator>
<dc:creator>Chikako Nagasato</dc:creator>
<dc:creator>Delphine Nègre</dc:creator>
<dc:creator>Eric Pelletier</dc:creator>
<dc:creator>Naomi Phillips</dc:creator>
<dc:creator>Philippe Potin</dc:creator>
<dc:creator>Stefan A Rensing</dc:creator>
<dc:creator>Ellyn Rousselot</dc:creator>
<dc:creator>Sylvie Rousvoal</dc:creator>
<dc:creator>Declan Schroeder</dc:creator>
<dc:creator>Delphine Scornet</dc:creator>
<dc:creator>Anne Siegel</dc:creator>
<dc:creator>Leila Tirichine</dc:creator>
<dc:creator>Thierry Tonon</dc:creator>
<dc:creator>Klaus Valentin</dc:creator>
<dc:creator>Heroen Verbruggen</dc:creator>
<dc:creator>Florian Weinberger</dc:creator>
<dc:creator>Glen Wheeler</dc:creator>
<dc:creator>Hiroshi Kawai</dc:creator>
<dc:creator>Akira F Peters</dc:creator>
<dc:creator>Hwan Su Yoon</dc:creator>
<dc:creator>Cécile Hervé</dc:creator>
<dc:creator>Naihao Ye</dc:creator>
<dc:creator>Eric Bapteste</dc:creator>
<dc:creator>Myriam Valero</dc:creator>
<dc:creator>Gabriel V Markov</dc:creator>
<dc:creator>Erwan Corre</dc:creator>
<dc:creator>Susana M Coelho</dc:creator>
<dc:creator>Patrick Wincker</dc:creator>
<dc:creator>Jean-Marc Aury</dc:creator>
<dc:creator>J Mark Cock</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Evolutionary genomics of the emergence of brown algae as key components of coastal ecosystems</dc:title>
<dc:identifier>pmid:39571576</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.049</dc:identifier>
</item>
<item>
<title>Advanced Imaging Assessment of the Impact of Tricuspid Regurgitation on Cardiac Remodeling: The TRILUMINATE Pivotal Imaging Substudy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570246/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Advanced imaging from the TRILUMINATE Pivotal imaging substudy demonstrated that TriClip effectively reduced TR. Significant cardiac remodeling was observed at 30 days and sustained at 1 year. With TriClip, the extent of cardiac remodeling was associated with the degree of TR reduction. (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal; NCT03904147).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 30:S0735-1097(24)08459-6. doi: 10.1016/j.jacc.2024.09.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The impact of tricuspid regurgitation (TR) on cardiac remodeling has not been thoroughly studied in a randomized controlled trial using advanced imaging.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this analysis was to provide comparative longitudinal changes in right heart remodeling using cardiac magnetic resonance and time-resolved functional computed tomography (4D-CT) in patients with symptomatic severe TR randomized to TriClip vs medical therapy (control).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: TRILUMINATE Pivotal (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal) is an international randomized controlled trial in symptomatic patients with severe TR. A prospective imaging substudy was performed on TRILUMINATE Pivotal subjects at 10 sites. Cardiac magnetic resonance and 4D-CT were performed following dedicated imaging protocols at baseline and at 30 days, and a final 4D-CT at 1 year (all assessed by an imaging core lab).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Sixty-nine randomized subjects (31 TriClip, 38 control) were enrolled. TR volume significantly decreased with TriClip at 30 days (P &lt; 0.0001; 70% reduction). A strong association (r = 0.90; P &lt; 0.0001) was observed between changes in TR volume and right ventricular end-diastolic volume at 30 days. Significant reductions in right ventricular end-diastolic volume (12% reduction; P &lt; 0.001) and tricuspid annular area (11% reduction; P &lt; 0.0001) were seen at 30 days and sustained through 1 year with TriClip. No meaningful changes were observed in the control group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Advanced imaging from the TRILUMINATE Pivotal imaging substudy demonstrated that TriClip effectively reduced TR. Significant cardiac remodeling was observed at 30 days and sustained at 1 year. With TriClip, the extent of cardiac remodeling was associated with the degree of TR reduction. (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal; NCT03904147).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570246/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39570246</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.009>10.1016/j.jacc.2024.09.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570246</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>João L Cavalcante</dc:creator>
<dc:creator>Markus Scherer</dc:creator>
<dc:creator>Miho Fukui</dc:creator>
<dc:creator>Stamatios Lerakis</dc:creator>
<dc:creator>Serge Harb</dc:creator>
<dc:creator>Amit Pursnani</dc:creator>
<dc:creator>Jonathan G Schwartz</dc:creator>
<dc:creator>Samir Kapadia</dc:creator>
<dc:creator>Mark J Ricciardi</dc:creator>
<dc:creator>Omar Khalique</dc:creator>
<dc:creator>Susheel Kodali</dc:creator>
<dc:creator>Dipan Shah</dc:creator>
<dc:creator>Steven H Little</dc:creator>
<dc:creator>Nishant Sekaran</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Peter Flueckiger</dc:creator>
<dc:creator>Pradeep Yadav</dc:creator>
<dc:creator>Abbas Emaminia</dc:creator>
<dc:creator>Wayne Batchelor</dc:creator>
<dc:creator>Peter Kellman</dc:creator>
<dc:creator>Zexu Lin</dc:creator>
<dc:creator>Phillip M Trusty</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>David Adams</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advanced Imaging Assessment of the Impact of Tricuspid Regurgitation on Cardiac Remodeling: The TRILUMINATE Pivotal Imaging Substudy</dc:title>
<dc:identifier>pmid:39570246</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.009</dc:identifier>
</item>
<item>
<title>Anatomic and Physiologic Repair of Congenitally Corrected Transposition of the Great Arteries</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Anatomic repair of ccTGA patients results in higher overall and reintervention-free survival compared to physiologic repair. Specifically, patients who had anatomic repair at &lt;5 years of age or who had preoperative pulmonary artery banding have better survival.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 14:S0735-1097(24)09770-5. doi: 10.1016/j.jacc.2024.07.056. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Congenitally corrected transposition of the great arteries (ccTGA) is a rare cardiac anomaly. The management strategy historically consisted of physiologic repair, leaving the morphologic right ventricle to support the systemic circulation. More recently, anatomic repair has been implemented to bring the left ventricle into the systemic circulation. Uncertainty persists about which repair strategy has the best outcome.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This meta-analysis aimed to summarize the long-term mortality risks following anatomic and physiologic repair of ccTGA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PubMed, Embase, and the Cochrane Database were searched. Data were extracted using prespecified data forms. The primary outcome was the composite risk of all-cause mortality or heart transplantation during hospitalization and at 1, 5, and 10 years of follow-up. Secondary outcomes included reintervention risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Forty-seven studies totaling 2,844 patients were included. The incidence risk of mortality at 10 years was 11.7% (95% CI: 8.5%-15.3%) and 17.4% (95% CI: 12.4%-23.0%) in the anatomic and physiologic repair groups, respectively. The incidence risk of reintervention at 10 years was 24.5% (95% CI: 19.2%-30.1%) and 30.3% (95% CI: 23.5%-37.6%), respectively. The primary outcome was significantly lower at 10 years in anatomically repaired patients who had surgery at &lt;5 years of age and who had preoperative pulmonary artery banding (P<sub>heterogeneity</sub> &lt; 0.01).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Anatomic repair of ccTGA patients results in higher overall and reintervention-free survival compared to physiologic repair. Specifically, patients who had anatomic repair at &lt;5 years of age or who had preoperative pulmonary artery banding have better survival.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39570245</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.056>10.1016/j.jacc.2024.07.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570245</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Kirolos A Jacob</dc:creator>
<dc:creator>Jürgen Hörer</dc:creator>
<dc:creator>Viktor Hraska</dc:creator>
<dc:creator>Valirie N Agbor</dc:creator>
<dc:creator>Saniyé Duchateau</dc:creator>
<dc:creator>Abraham van Wijk</dc:creator>
<dc:creator>David J Barron</dc:creator>
<dc:creator>Paul H Schoof</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anatomic and Physiologic Repair of Congenitally Corrected Transposition of the Great Arteries</dc:title>
<dc:identifier>pmid:39570245</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.056</dc:identifier>
</item>
<item>
<title>Getting Imaging Right: Multimodal Assessment of Right-Sided Heart Function in Patients Undergoing Tricuspid Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570244/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 14:S0735-1097(24)10030-7. doi: 10.1016/j.jacc.2024.10.077. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570244/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39570244</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.077>10.1016/j.jacc.2024.10.077</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570244</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mathias Orban</dc:creator>
<dc:creator>Nicole Karam</dc:creator>
<dc:creator>Lukas Stolz</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:creator>Jörg Hausleiter</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Getting Imaging Right: Multimodal Assessment of Right-Sided Heart Function in Patients Undergoing Tricuspid Repair</dc:title>
<dc:identifier>pmid:39570244</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.077</dc:identifier>
</item>
<item>
<title>Congenitally Corrected Transposition of the Great Arteries: The Impact of Anatomic vs Physiologic Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570243/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 25:S0735-1097(24)09769-9. doi: 10.1016/j.jacc.2024.07.055. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570243/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39570243</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.055>10.1016/j.jacc.2024.07.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570243</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tara Karamlou</dc:creator>
<dc:creator>Justin Robinson</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Congenitally Corrected Transposition of the Great Arteries: The Impact of Anatomic vs Physiologic Repair</dc:title>
<dc:identifier>pmid:39570243</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.055</dc:identifier>
</item>
<item>
<title>5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570242/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The 5-year outcomes from the largest randomized LAAO clinical trial demonstrated the long-term safety and effectiveness of the Amulet occluder and Watchman 2.5 devices. The dual-seal Amulet occluder reduces atrial fibrillation-related thromboembolic events while eliminating the need for long-term OAC. (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial [Amulet IDE trial]; NCT02879448).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 15:S0735-1097(24)10313-0. doi: 10.1016/j.jacc.2024.10.101. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The Amulet IDE trial (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial) evaluated the safety and effectiveness of the Amulet occluder (Abbott) in patients with nonvalvular atrial fibrillation. The Amulet IDE trial is the largest randomized LAAO trial, comparing the Amulet occluder with the Watchman 2.5 device (Boston Scientific).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This analysis presents the 5-year results from the trial comparing the 2 devices head to head.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients enrolled in the Amulet IDE trial were at a high risk of stroke or systemic embolism defined as a CHADS2 score ≥2 or CHA2DS2-VASc score ≥3. Oral anticoagulation (OAC) use and key clinical outcomes are presented through 5 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1,878 patients were randomized, with 1,833 undergoing a device implantation attempt (n = 917, Amulet occluder; and n = 916, Watchman device). A significantly higher percentage of patients were free of OAC in the Amulet occluder group at each follow-up visit, with 94.0% and 90.9% free of OAC at the last 5-year follow-up visit in the Amulet and Watchman device groups, respectively (P = 0.009). The 5-year clinical outcomes were similar between the Amulet and Watchman devices, including the composite of ischemic stroke or systemic embolism (7.4% vs 7.1%; P = 0.851), the composite of stroke, systemic embolism, or cardiovascular death (20.3% vs 20.7%; P = 0.666), major bleeding (20.1% vs 20.0%; P = 0.882), cardiovascular (CV) death (14.3% vs 15.4%; P = 0.429), and all-cause death (28.7% vs 31.1%; P = 0.217). Annualized ischemic stroke rates at 5 years were low and the same for Amulet (1.6%/y) and Watchman (1.6%/y) devices. Strokes in patients with the Amulet occluder were less severe (n = 38, nondisabling; n = 11, disabling; n = 11, fatal; n = 12, unknown) than strokes in patients with the Watchman device (n = 19, nondisabling; n = 22, disabling; n = 17, fatal; n = 10, unknown). Moreover, device factors (device-related thrombus or peridevice leak ≥3 mm) preceded stroke events and CV deaths more frequently in patients with the Watchman device (n = 63) compared with patients with the Amulet occluder (n = 31).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The 5-year outcomes from the largest randomized LAAO clinical trial demonstrated the long-term safety and effectiveness of the Amulet occluder and Watchman 2.5 devices. The dual-seal Amulet occluder reduces atrial fibrillation-related thromboembolic events while eliminating the need for long-term OAC. (AMPLATZER Amulet Left Atrial Appendage Occluder [LAAO] Investigational Device Exemption [IDE] Trial [Amulet IDE trial]; NCT02879448).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570242/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39570242</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.101>10.1016/j.jacc.2024.10.101</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570242</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dhanunjaya Lakkireddy</dc:creator>
<dc:creator>Christopher R Ellis</dc:creator>
<dc:creator>David Thaler</dc:creator>
<dc:creator>Vijendra Swarup</dc:creator>
<dc:creator>Alok Gambhir</dc:creator>
<dc:creator>James Hermiller</dc:creator>
<dc:creator>Jens Erik Nielsen-Kudsk</dc:creator>
<dc:creator>Stephen Worthley</dc:creator>
<dc:creator>Devi Nair</dc:creator>
<dc:creator>Boris Schmidt</dc:creator>
<dc:creator>Rodney Horton</dc:creator>
<dc:creator>Nigel Gupta</dc:creator>
<dc:creator>Jordan A Anderson</dc:creator>
<dc:creator>Hong Zhao</dc:creator>
<dc:creator>Mohamad Alkhouli</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:39570242</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.101</dc:identifier>
</item>
<item>
<title>Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570241/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The RF-SLAM algorithm accurately predicted all-cause mortality and death/HF hospitalization at 3 months and 1 year during the first 5 years of device implant, demonstrating good internal and external validity. Prospective studies and randomized trials are needed to evaluate model performance in other populations and settings and to determine its impact on patient outcomes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15:S0735-1097(24)08455-9. doi: 10.1016/j.jacc.2024.09.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Predicting the clinical trajectory of individual patients with implantable cardioverter-defibrillators (ICDs) is essential to inform clinical care. Machine learning approaches can potentially overcome the limitations of conventional statistical methods and provide more accurate, personalized risk estimates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We sought to develop and externally validate a novel machine learning algorithm for predicting all-cause mortality and/or heart failure (HF) hospitalization in ICD patients with and without cardiac resynchronization therapy (CRT) using variables that are readily available to treating clinicians. We also sought to identify key factors that separate patients along a continuum of risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Random forest for survival, longitudinal, and multivariate (RF-SLAM) data analysis was applied to predict 3-month and 1-year risks for all-cause mortality and a composite outcome of death/HF hospitalization during the first 5 years of device implant. Models were trained using a nationwide cohort from the Veterans Health Administration. Three models were sequentially tested, and external validation was performed in a separate nonveteran clinical registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The training and validation cohorts included 12,043 patients (age 67.5 ± 9.4 years) and 1,394 patients (age 66.3 ± 11.9 years), respectively. Median follow-up was 3.3 years for the training cohort and 3.6 years for validation cohort. The most accurate models for both outcomes included baseline demographics entered at the time of ICD implant (age, sex, CRT therapy) and time-varying ICD data with area under the receiver-operating characteristic curve for predicting death at 3 months (0.91; 95% CI: 0.87-0.94) and 1 year (0.80; 95% CI: 0.78-0.82); death/HF hospitalization at 3 months (0.81; 95% CI: 0.79-0.83) and 1 year (0.71; 95% CI: 0.70-0.72). Models demonstrated high discrimination and good calibration in the validation cohort. Additionally, time-varying physiologic data from ICDs, especially daily physical activity, had substantial importance in predicting outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The RF-SLAM algorithm accurately predicted all-cause mortality and death/HF hospitalization at 3 months and 1 year during the first 5 years of device implant, demonstrating good internal and external validity. Prospective studies and randomized trials are needed to evaluate model performance in other populations and settings and to determine its impact on patient outcomes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570241/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39570241</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.006>10.1016/j.jacc.2024.09.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570241</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Lindsey Rosman</dc:creator>
<dc:creator>Rachel Lampert</dc:creator>
<dc:creator>Kaicheng Wang</dc:creator>
<dc:creator>Anil K Gehi</dc:creator>
<dc:creator>James Dziura</dc:creator>
<dc:creator>Elena Salmoirago-Blotcher</dc:creator>
<dc:creator>Cynthia Brandt</dc:creator>
<dc:creator>Samuel F Sears</dc:creator>
<dc:creator>Matthew Burg</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators</dc:title>
<dc:identifier>pmid:39570241</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.006</dc:identifier>
</item>
<item>
<title>Adding AI to the Toolkit for Patients With Implantable Cardioverter-Defibrillators</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 13:S0735-1097(24)09962-5. doi: 10.1016/j.jacc.2024.10.072. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39570240</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.072>10.1016/j.jacc.2024.10.072</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570240</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Archana Ramireddy</dc:creator>
<dc:creator>Eric D Braunstein</dc:creator>
<dc:creator>Sumeet S Chugh</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Adding AI to the Toolkit for Patients With Implantable Cardioverter-Defibrillators</dc:title>
<dc:identifier>pmid:39570240</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.072</dc:identifier>
</item>
<item>
<title>Worsening Heart Failure: An Opportunity for Treatment Implementation Even With a Preserved Ejection Fraction?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39570239/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 29:S0735-1097(24)08531-0. doi: 10.1016/j.jacc.2024.09.022. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39570239/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39570239</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.022>10.1016/j.jacc.2024.09.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39570239</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Felix Lindberg</dc:creator>
<dc:creator>Gianluigi Savarese</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Worsening Heart Failure: An Opportunity for Treatment Implementation Even With a Preserved Ejection Fraction?</dc:title>
<dc:identifier>pmid:39570239</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.022</dc:identifier>
</item>
<item>
<title>A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39569515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings reveal a substantial cardiomyocyte regeneration potential in human heart disease, which could be exploited therapeutically.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.123.067156. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiomyocytes in the adult human heart show a regenerative capacity, with an annual renewal rate of ≈0.5%. Whether this regenerative capacity of human cardiomyocytes is employed in heart failure has been controversial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We determined cardiomyocyte renewal in 52 patients with advanced heart failure, 28 of whom received left ventricular assist device support. We measured the concentration of nuclear bomb test-derived <sup>14</sup>C in cardiomyocyte genomic DNA and performed mathematical modeling to establish cardiomyocyte renewal in heart failure with and without LVAD unloading.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We show that cardiomyocyte generation is minimal in end-stage heart failure patients at rates 18 to 50× lower compared with the healthy heart. However, patients receiving left ventricle support device therapy, who showed significant functional and structural cardiac improvement, had a >;6-fold increase in cardiomyocyte renewal relative to the healthy heart.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings reveal a substantial cardiomyocyte regeneration potential in human heart disease, which could be exploited therapeutically.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39569515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39569515</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067156>10.1161/CIRCULATIONAHA.123.067156</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39569515</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Wouter Derks</dc:creator>
<dc:creator>Julian Rode</dc:creator>
<dc:creator>Sofia Collin</dc:creator>
<dc:creator>Fabian Rost</dc:creator>
<dc:creator>Paula Heinke</dc:creator>
<dc:creator>Anjana Hariharan</dc:creator>
<dc:creator>Lauren Pickel</dc:creator>
<dc:creator>Irina Simonova</dc:creator>
<dc:creator>Enikő Lázár</dc:creator>
<dc:creator>Evan Graham</dc:creator>
<dc:creator>Ramadan Jashari</dc:creator>
<dc:creator>Michaela Andrä</dc:creator>
<dc:creator>Anders Jeppsson</dc:creator>
<dc:creator>Mehran Salehpour</dc:creator>
<dc:creator>Kanar Alkass</dc:creator>
<dc:creator>Henrik Druid</dc:creator>
<dc:creator>Christos P Kyriakopoulos</dc:creator>
<dc:creator>Iosif Taleb</dc:creator>
<dc:creator>Thirupura S Shankar</dc:creator>
<dc:creator>Craig H Selzman</dc:creator>
<dc:creator>Hesham Sadek</dc:creator>
<dc:creator>Stefan Jovinge</dc:creator>
<dc:creator>Lutz Brusch</dc:creator>
<dc:creator>Jonas Frisén</dc:creator>
<dc:creator>Stavros Drakos</dc:creator>
<dc:creator>Olaf Bergmann</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease</dc:title>
<dc:identifier>pmid:39569515</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067156</dc:identifier>
</item>
<item>
<title>Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39569504/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Decreased FXI level is associated with greater incidence of HF, especially in older adults. It is also associated with prevalent AF, worse diastolic function, worse LA function, and greater LA size. More research is needed to assess potential unwanted effects of FXI inhibition on the risk of cardiovascular events and cardiac function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.124.070278. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Coagulation factor XI (FXI) inhibitors are a promising and novel class of anticoagulants, but a recent animal study found that FXI inhibition exacerbated diastolic dysfunction and heart failure (HF). In the ARIC study (Atherosclerosis Risk in Communities), we investigated whether plasma FXI level was associated with cardiovascular events and cardiac function.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: ARIC was our primary analytic cohort. We included 4471 participants (median age, 75 years; 57% female; 17% Black) who attended visit 5 (2011-2013) with Somalogic-quantified plasma FXI levels and echocardiographic cardiac function. Prevalent HF and atrial fibrillation (AF) cases were defined as having HF or AF diagnosed at or before each participant's visit 5 exam date. Incident HF and AF events were ascertained through 2021. Associations were assessed using Cox, logistic, and linear regression models. Primary prospective associations were also validated in the CHS (Cardiovascular Health Study) using an orthogonal FXI assay (enzyme-linked immunosorbent assay).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: At ARIC visit 5, there were 665 and 419 participants with prevalent HF and AF, respectively. During a median follow-up of 9 years, there were 580 and 788 incident HF and AF events, respectively. Lower FXI level was associated prospectively with higher incidence of HF (hazard ratio [HR], 1.36 [for each 1-unit decrement of log<sub>2</sub>-transformed FXI level] [95% CI, 1.01-1.83]) but not incident AF, and cross-sectionally with increased odds of AF (odds ratio [OR], 1.96 [95% CI, 1.23-3.07]) but not HF. In age-stratified analyses, decreased FXI was associated with higher incidence of HF in participants ≥75 years of age (HR, 1.57 [95% CI, 1.08-2.28]) but not &lt;75 years of age (HR, 1.11 [95% CI, 0.68-1.79]). The inverse FXI-HF association was validated in CHS (HR, 1.18 [95% CI, 1.02-1.36]). At ARIC visit 5, lower FXI level was also associated with higher prevalence of diastolic dysfunction and worse E/A ratio, left atrial (LA) volume index, LA function, and left ventricular mass index, but not left ventricular ejection fraction or global longitudinal strain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Decreased FXI level is associated with greater incidence of HF, especially in older adults. It is also associated with prevalent AF, worse diastolic function, worse LA function, and greater LA size. More research is needed to assess potential unwanted effects of FXI inhibition on the risk of cardiovascular events and cardiac function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39569504/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39569504</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070278>10.1161/CIRCULATIONAHA.124.070278</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39569504</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuekai Ji</dc:creator>
<dc:creator>Michael J Zhang</dc:creator>
<dc:creator>Wendy Wang</dc:creator>
<dc:creator>Faye L Norby</dc:creator>
<dc:creator>Anne A Eaton</dc:creator>
<dc:creator>Riccardo M Inciardi</dc:creator>
<dc:creator>Alvaro Alonso</dc:creator>
<dc:creator>Sanaz Sedaghat</dc:creator>
<dc:creator>Peter Ganz</dc:creator>
<dc:creator>Jeremy Van't Hof</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Paulo H M Chaves</dc:creator>
<dc:creator>Susan R Heckbert</dc:creator>
<dc:creator>Amil M Shah</dc:creator>
<dc:creator>Lin Yee Chen</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS</dc:title>
<dc:identifier>pmid:39569504</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070278</dc:identifier>
</item>
<item>
<title>S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39569500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: S100A1ct is a promising lead for the development of novel peptide-based therapeutics against heart failure with reduced ejection fraction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 21. doi: 10.1161/CIRCULATIONAHA.123.066961. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The EF-hand Ca<sup>2+</sup> sensor protein S100A1 has been identified as a molecular regulator and enhancer of cardiac performance. The ability of S100A1 to recognize and modulate the activity of targets such as SERCA2a (sarcoplasmic reticulum Ca<sup>2+</sup> ATPase) and RyR2 (ryanodine receptor 2) in cardiomyocytes has mostly been ascribed to its hydrophobic C-terminal α-helix (residues 75-94). We hypothesized that a synthetic peptide consisting of residues 75 through 94 of S100A1 and an N-terminal solubilization tag (S100A1ct) could mimic the performance-enhancing effects of S100A1 and may be suitable as a peptide therapeutic to improve the function of diseased hearts.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We applied an integrative translational research pipeline ranging from in silico computational molecular modeling and in vitro biochemical molecular assays as well as isolated rodent and human cardiomyocyte performance assessments to in vivo safety and efficacy studies in small and large animal cardiac disease models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We characterize S100A1ct as a cell-penetrating peptide with positive inotropic and antiarrhythmic properties in normal and failing myocardium in vitro and in vivo. This activity translates into improved contractile performance and survival in preclinical heart failure models with reduced ejection fraction after S100A1ct systemic administration. S100A1ct exerts a fast and sustained dose-dependent enhancement of cardiomyocyte Ca<sup>2+</sup> cycling and prevents β-adrenergic receptor-triggered Ca<sup>2+</sup> imbalances by targeting SERCA2a and RyR2 activity. In line with the S100A1ct-mediated enhancement of SERCA2a activity, modeling suggests an interaction of the peptide with the transmembrane segments of the sarcoplasmic Ca<sup>2+</sup> pump. Incorporation of a cardiomyocyte-targeting peptide tag into S100A1ct (cor-S100A1ct) further enhanced its biological and therapeutic potency in vitro and in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: S100A1ct is a promising lead for the development of novel peptide-based therapeutics against heart failure with reduced ejection fraction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39569500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39569500</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066961>10.1161/CIRCULATIONAHA.123.066961</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39569500</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Dorothea Kehr</dc:creator>
<dc:creator>Julia Ritterhoff</dc:creator>
<dc:creator>Manuel Glaser</dc:creator>
<dc:creator>Lukas Jarosch</dc:creator>
<dc:creator>Rafael E Salazar</dc:creator>
<dc:creator>Kristin Spaich</dc:creator>
<dc:creator>Karl Varadi</dc:creator>
<dc:creator>Jennifer Birkenstock</dc:creator>
<dc:creator>Michael Egger</dc:creator>
<dc:creator>Erhe Gao</dc:creator>
<dc:creator>Walter J Koch</dc:creator>
<dc:creator>Max Sauter</dc:creator>
<dc:creator>Marc Freichel</dc:creator>
<dc:creator>Hugo A Katus</dc:creator>
<dc:creator>Norbert Frey</dc:creator>
<dc:creator>Andreas Jungmann</dc:creator>
<dc:creator>Cornelius Busch</dc:creator>
<dc:creator>Paul J Mather</dc:creator>
<dc:creator>Arjang Ruhparwar</dc:creator>
<dc:creator>Martin Busch</dc:creator>
<dc:creator>Mirko Völkers</dc:creator>
<dc:creator>Rebecca C Wade</dc:creator>
<dc:creator>Patrick Most</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models</dc:title>
<dc:identifier>pmid:39569500</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066961</dc:identifier>
</item>
<item>
<title>Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39569497/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>Right ventricular outflow dysfunction, manifesting as stenosis, regurgitation, or both, is nearly universal in patients with repaired tetralogy of Fallot, precipitating a complex pathophysiological cascade that leads to increasing rates of morbidity and mortality with advancing age. As the number of adolescent and adult patients with repaired tetralogy of Fallot continues to grow as a result of excellent survival during infancy, the need to improve late outcomes has become an urgent priority....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 21. doi: 10.1161/CIR.0000000000001291. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Right ventricular outflow dysfunction, manifesting as stenosis, regurgitation, or both, is nearly universal in patients with repaired tetralogy of Fallot, precipitating a complex pathophysiological cascade that leads to increasing rates of morbidity and mortality with advancing age. As the number of adolescent and adult patients with repaired tetralogy of Fallot continues to grow as a result of excellent survival during infancy, the need to improve late outcomes has become an urgent priority. This American Heart Association scientific statement provides an update on the current state of knowledge of the pathophysiology, methods of surveillance, risk stratification, and latest available therapies, including transcatheter and surgical pulmonary valve replacement strategies, as well as management of life-threatening arrhythmias. It reviews emerging evidence on the roles of comorbidities and patient-reported outcomes and their impact on quality of life. In addition, this scientific statement explores contemporary evidence for clinical choices such as transcatheter or surgical pulmonary valve replacement, discusses criteria and options for intervention for failing implanted bioprosthetic pulmonary valves, and considers a new approach to determining optimal timing and indications for pulmonary valve replacement.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39569497/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39569497</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001291>10.1161/CIR.0000000000001291</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39569497</guid>
<pubDate>Thu, 21 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tal Geva</dc:creator>
<dc:creator>Rachel M Wald</dc:creator>
<dc:creator>Emily Bucholz</dc:creator>
<dc:creator>James F Cnota</dc:creator>
<dc:creator>Doff B McElhinney</dc:creator>
<dc:creator>Laura M Mercer-Rosa</dc:creator>
<dc:creator>Carlos M Mery</dc:creator>
<dc:creator>Andrea Leann Miles</dc:creator>
<dc:creator>Jeremy Moore</dc:creator>
<dc:creator>American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing</dc:creator>
<dc:date>2024-11-21</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Long-Term Management of Right Ventricular Outflow Tract Dysfunction in Repaired Tetralogy of Fallot: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39569497</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001291</dc:identifier>
</item>
<item>
<title>Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39568016/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SGLT2i reduced the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease. These findings suggest that SGLT2i implementation may have an important ancillary benefit on prevention or delay of diabetes in these high-risk populations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 21:ehae780. doi: 10.1093/eurheartj/ehae780. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Individuals with heart failure (HF), other forms of cardiovascular disease, or kidney disease are at increased risk for the development and adverse health effects of diabetes. As such, prevention or delay of diabetes is an important treatment priority in these groups. The aim of this meta-analysis was to determine the effect of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on incident diabetes in HF across the spectrum of left ventricular ejection fraction (LVEF) and across the broader spectrum of cardiovascular or kidney disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: First, the effects of dapagliflozin vs. placebo on new-onset diabetes were assessed in a pooled, participant-level analysis of the DAPA-HF and DELIVER trials. New-onset diabetes was defined as the new initiation of glucose-lowering therapy during follow-up, and time from randomization to new-onset diabetes was evaluated using Cox proportional hazards models. Second, PubMed and Embase were searched to identify large-scale randomized clinical outcomes trials (RCTs) comparing SGLT2i with placebo among adults with cardiovascular or kidney disease. A trial-level meta-analysis was then conducted to summarize the treatment effects of SGLT2i on the incidence of new-onset diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In the pooled analysis of DAPA-HF and DELIVER including 5623 participants with HF but without diabetes at baseline, dapagliflozin reduced the incidence of new-onset diabetes by 33% [hazard ratio (HR), 0.67; 95% confidence interval (CI), .49-.91; P = .012] when compared with placebo. There was no evidence of heterogeneity across the spectrum of continuous LVEF or key subgroups. Among seven complementary RCTs including 17 855 participants with cardiovascular or kidney disease, SGLT2i reduced the of new-onset diabetes by 26% (HR, 0.74; 95% CI .65-.85; P &lt; .001), with consistent effects across trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SGLT2i reduced the incidence of new-onset diabetes among individuals with cardiovascular or kidney disease. These findings suggest that SGLT2i implementation may have an important ancillary benefit on prevention or delay of diabetes in these high-risk populations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39568016/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39568016</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae780>10.1093/eurheartj/ehae780</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39568016</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>Mats C Højbjerg Lassen</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Zi Michael Miao</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Kieran F Docherty</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Magnus Petersson</dc:creator>
<dc:creator>Anna Maria Langkilde</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease</dc:title>
<dc:identifier>pmid:39568016</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae780</dc:identifier>
</item>
<item>
<title>Unlocking excellence in health care: the power of inclusive and sensitive language in medicine</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567622/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 20. doi: 10.1038/s41569-024-01101-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567622/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39567622</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01101-2>10.1038/s41569-024-01101-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567622</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sarah M Birkhoelzer</dc:creator>
<dc:creator>Sonia S Anand</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Unlocking excellence in health care: the power of inclusive and sensitive language in medicine</dc:title>
<dc:identifier>pmid:39567622</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01101-2</dc:identifier>
</item>
<item>
<title>Clinical Signs of Congestion in Younger Patients With Decompensated Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567052/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e323. doi: 10.1016/j.jacc.2024.08.079.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567052/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39567052</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.079>10.1016/j.jacc.2024.08.079</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567052</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jaimie Coburn</dc:creator>
<dc:creator>Pieter A Neef</dc:creator>
<dc:creator>Simon Hobson</dc:creator>
<dc:creator>Jonathan R Dalzell</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Signs of Congestion in Younger Patients With Decompensated Heart Failure</dc:title>
<dc:identifier>pmid:39567052</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.079</dc:identifier>
</item>
<item>
<title>Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567051/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e321. doi: 10.1016/j.jacc.2024.08.080.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567051/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39567051</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.080>10.1016/j.jacc.2024.08.080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567051</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Irene Santos-Pardo</dc:creator>
<dc:creator>Mikael Andersson Franko</dc:creator>
<dc:creator>Thomas Nyström</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</dc:title>
<dc:identifier>pmid:39567051</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.080</dc:identifier>
</item>
<item>
<title>Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567050/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e319-e320. doi: 10.1016/j.jacc.2024.07.062.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567050/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39567050</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.062>10.1016/j.jacc.2024.07.062</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567050</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Chao Liu</dc:creator>
<dc:creator>Ximing Li</dc:creator>
<dc:creator>Hongliang Cong</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Glycemic Control and Coronary Stent Failure in Patients With Type 2 Diabetes Mellitus</dc:title>
<dc:identifier>pmid:39567050</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.062</dc:identifier>
</item>
<item>
<title>Reply: Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567049/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e317-e318. doi: 10.1016/j.jacc.2024.08.081.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567049/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39567049</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.081>10.1016/j.jacc.2024.08.081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567049</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sarah Crook</dc:creator>
<dc:creator>Brett R Anderson</dc:creator>
<dc:creator>New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR)</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis</dc:title>
<dc:identifier>pmid:39567049</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.081</dc:identifier>
</item>
<item>
<title>Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39567048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241123090918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 26;84(22):e315. doi: 10.1016/j.jacc.2024.07.060.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39567048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241123090918&v=2.18.0.post9+e462414">39567048</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.060>10.1016/j.jacc.2024.07.060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39567048</guid>
<pubDate>Wed, 20 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Zhangxin Wen</dc:creator>
<dc:creator>Sihan Duan</dc:creator>
<dc:creator>Hong Liu</dc:creator>
<dc:date>2024-11-20</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Revealing the Hidden Layers: Focus on Social and Psychological Determinants in Congenital Heart Surgery Prognosis</dc:title>
<dc:identifier>pmid:39567048</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.060</dc:identifier>
</item>





























</channel>
</rss>